MAZE
Maze Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth +30.0% ·
share flow +30.0% ·
net new positions +20.0%
· formula
Broad accumulation: rising shares across more holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passive) | 1.33M | +218.1% | $34.62M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (passive) | 1.32M | +114.1% | $34.12M | 0.0% | ▲ Add | 2 | SEC ↗ ×6 |
| 3 | Marshall Wace ✦ | 777.70K | +3868.5% | $20.17M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 4 | Fidelity (FMR) ✦ | 655.61K | +18.2% | $17.00M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (passive) | 473.55K | +104.8% | $12.28M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 6 | State Street Global Advisors ✦ (passive) | 384.70K | +165.9% | $9.98M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 7 | Morgan Stanley ✦ | 212.76K | n/a | $5.52M | 0.0% | n/c | 1 | SEC ↗ ×7 |
| 8 | Renaissance Technologies ✦ | 86.10K | New | $2.23M | 0.0% | New | 1 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 27.61K | +0.5% | $716,057 | 0.0% | ▲ Add | 2 | SEC ↗ ×5 |
| 10 | JPMorgan Chase ✦ | 15.78K | n/a | $409,176 | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Two Sigma Investments ✦ | 11.15K | New | $289,120 | 0.0% | New | 1 | SEC ↗ |
| 12 | T. Rowe Price ✦ | 10.47K | New | $272,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Renaissance Technologies | $2.23M | 0.0% |
| Two Sigma Investments | $289,120 | 0.0% |
| T. Rowe Price | $272,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 164 holders, 51.62M shares, $1.52B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 31.91K sh · $862,186
Officer, Director · 2.59K sh · $70,073
Officer · 16.14K sh · $434,743
Officer · 7.50K sh · $202,921
Officer · 9.71K sh · $254,502
Officer · 59 sh · $1,521
Officer · 5.13K sh · $133,448
Officer, Director · 129 sh · $3,325
Officer, Director · 11.28K sh · $293,482
Officer · 36 sh · $929
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology